| Company Name: |
Shanghai YuanYe Biotechnology Co., Ltd.
|
| Tel: |
13636370518 |
| Email: |
shyysw007@163.com |
| Products Intro: |
Product Name:Pamrevlumab (anti-CTGF)
CAS:946415-13-0
Purity:Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human I Package:5mg Remarks:K10646
|
| Company Name: |
Guangzhou Hongyuan Chemical Co.,Ltd
|
| Tel: |
15817493340 |
| Email: |
981810490@qq.com |
| Products Intro: |
Product Name:Pamrevlumab
CAS:946415-13-0
Purity:95% Package:1mg;1g;100g
|
Pamrevlumab manufacturers
- Pamrevlumab
-
- $139.00
-
2026-07-13
- CAS:946415-13-0
- Purity: 95.00%
- Supply Ability: 10g
|
| | Pamrevlumab Basic information |
| Product Name: | Pamrevlumab | | Synonyms: | Pamrevlumab;Research Grade Pamrevlumab(DHD82301);Research Grade Pamrevlumab;Pamrevlumab (anti-CTGF);FG-3019 | | CAS: | 946415-13-0 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Pamrevlumab Structure]() |
| | Pamrevlumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Pamrevlumab Usage And Synthesis |
| Uses | FG-3019 (Pamrevlumab) is a recombinant human antibody that binds to connective tissue growth factor (CTGF). FG-3019 can be used for the research of idiopathic pulmonary fibrosis (IPF)[1][2]. | | in vivo | FG-3019 (30 mg/kg; i.p. every 3 d for 9 d) in combination with Gemcitabine acutely decreases mouse pancreatic ductal adenocarcinoma (PDA) growth and induces neoplastic cell apoptosis in LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre (KPC) mice[2]. | | References | [1] Sgalla G, et, al. Pamrevlumab for the treatment of idiopathic pulmonary fibrosis. Expert Opin Investig Drugs. 2020 Aug;29(8):771-777. DOI:10.1080/13543784.2020.1773790
[2] Neesse A, et, al. CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer. Proc Natl Acad Sci U S A. 2013 Jul 23;110(30):12325-30. DOI:10.1073/pnas.1300415110 |
| | Pamrevlumab Preparation Products And Raw materials |
|